123 related articles for article (PubMed ID: 27179218)
1. Identification of a novel inherited ALK variant M1199L in the WNT type of medulloblastoma.
Trubicka J; Szperl M; Grajkowska W; Karkucińska-Więckowska A; Tarasińska M; Falana K; Dembowska-Bagińska B; Łastowska M
Folia Neuropathol; 2016; 54(1):23-30. PubMed ID: 27179218
[TBL] [Abstract][Full Text] [Related]
2. ALK Expression Is a Novel Marker for the WNT-activated Type of Pediatric Medulloblastoma and an Indicator of Good Prognosis for Patients.
Łastowska M; Trubicka J; Niemira M; Paczkowska-Abdulsalam M; Karkucińska-Więckowska A; Kaleta M; Drogosiewicz M; Tarasińska M; Perek-Polnik M; Krętowski A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Matyja E
Am J Surg Pathol; 2017 Jun; 41(6):781-787. PubMed ID: 28338501
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical detection of ALK protein identifies APC mutated medulloblastoma and differentiates the WNT-activated medulloblastoma from other types of posterior fossa childhood tumors.
Łastowska M; Trubicka J; Karkucińska-Więckowska A; Kaleta M; Tarasińska M; Perek-Polnik M; Sobocińska AA; Dembowska-Bagińska B; Grajkowska W; Matyja E
Brain Tumor Pathol; 2019 Jan; 36(1):1-6. PubMed ID: 30523493
[TBL] [Abstract][Full Text] [Related]
4. Identification of ALK germline mutation (3605delG) in pediatric anaplastic medulloblastoma.
Coco S; De Mariano M; Valdora F; Servidei T; Ridola V; Andolfo I; Oberthuer A; Tonini GP; Longo L
J Hum Genet; 2012 Oct; 57(10):682-4. PubMed ID: 22810114
[TBL] [Abstract][Full Text] [Related]
5. Characterization of anaplastic lymphoma kinase-positive medulloblastomas.
Yan B; Kuick CH; Lim M; Yong MH; Lee CK; Low SYY; Low DCY; Lim D; Soh SY; Chang KTE
J Clin Neurosci; 2016 Jan; 23():120-122. PubMed ID: 26474502
[TBL] [Abstract][Full Text] [Related]
6. [Expression of anaplastic lymphoma kinase clone 1A4 in pediatric medulloblastoma and its significance].
Zhao ML; Zhao Y; Shen ZP; Gu WZ; Liu L; Shu Y; Chang DE; Tang HF
Zhonghua Bing Li Xue Za Zhi; 2020 Jan; 49(1):52-56. PubMed ID: 31914535
[No Abstract] [Full Text] [Related]
7. Contrast enhancement pattern predicts poor survival for patients with non-WNT/SHH medulloblastoma tumours.
Łastowska M; Jurkiewicz E; Trubicka J; Daszkiewicz P; Drogosiewicz M; Malczyk K; Grajkowska W; Matyja E; Cukrowska B; Pronicki M; Perek-Polnik M; Perek D; Dembowska-Bagińska B
J Neurooncol; 2015 May; 123(1):65-73. PubMed ID: 25862008
[TBL] [Abstract][Full Text] [Related]
8. Dissecting the genomic complexity underlying medulloblastoma.
Jones DT; Jäger N; Kool M; Zichner T; Hutter B; Sultan M; Cho YJ; Pugh TJ; Hovestadt V; Stütz AM; Rausch T; Warnatz HJ; Ryzhova M; Bender S; Sturm D; Pleier S; Cin H; Pfaff E; Sieber L; Wittmann A; Remke M; Witt H; Hutter S; Tzaridis T; Weischenfeldt J; Raeder B; Avci M; Amstislavskiy V; Zapatka M; Weber UD; Wang Q; Lasitschka B; Bartholomae CC; Schmidt M; von Kalle C; Ast V; Lawerenz C; Eils J; Kabbe R; Benes V; van Sluis P; Koster J; Volckmann R; Shih D; Betts MJ; Russell RB; Coco S; Tonini GP; Schüller U; Hans V; Graf N; Kim YJ; Monoranu C; Roggendorf W; Unterberg A; Herold-Mende C; Milde T; Kulozik AE; von Deimling A; Witt O; Maass E; Rössler J; Ebinger M; Schuhmann MU; Frühwald MC; Hasselblatt M; Jabado N; Rutkowski S; von Bueren AO; Williamson D; Clifford SC; McCabe MG; Collins VP; Wolf S; Wiemann S; Lehrach H; Brors B; Scheurlen W; Felsberg J; Reifenberger G; Northcott PA; Taylor MD; Meyerson M; Pomeroy SL; Yaspo ML; Korbel JO; Korshunov A; Eils R; Pfister SM; Lichter P
Nature; 2012 Aug; 488(7409):100-5. PubMed ID: 22832583
[TBL] [Abstract][Full Text] [Related]
9. Molecular stratification of medulloblastoma: comparison of histological and genetic methods to detect Wnt activated tumours.
Goschzik T; Zur Mühlen A; Kristiansen G; Haberler C; Stefanits H; Friedrich C; von Hoff K; Rutkowski S; Pfister SM; Pietsch T
Neuropathol Appl Neurobiol; 2015 Feb; 41(2):135-44. PubMed ID: 24894640
[TBL] [Abstract][Full Text] [Related]
10. DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas.
Korshunov A; Sahm F; Zheludkova O; Golanov A; Stichel D; Schrimpf D; Ryzhova M; Potapov A; Habel A; Meyer J; Lichter P; Jones DTW; von Deimling A; Pfister SM; Kool M
Neuro Oncol; 2019 Feb; 21(2):214-221. PubMed ID: 30252101
[TBL] [Abstract][Full Text] [Related]
11. ALK kinase domain mutations in primary anaplastic large cell lymphoma: consequences on NPM-ALK activity and sensitivity to tyrosine kinase inhibitors.
Lovisa F; Cozza G; Cristiani A; Cuzzolin A; Albiero A; Mussolin L; Pillon M; Moro S; Basso G; Rosolen A; Bonvini P
PLoS One; 2015; 10(4):e0121378. PubMed ID: 25874976
[TBL] [Abstract][Full Text] [Related]
12. Simplified Molecular Subtyping of Medulloblastoma for Reduced Cost and Improved Turnaround Time.
Shuangshoti S; Tadadontip P; Techavichit P; Thorner PS; Shuangshoti S; Teerapakpinyo C
Appl Immunohistochem Mol Morphol; 2020 Aug; 28(7):538-543. PubMed ID: 31343993
[TBL] [Abstract][Full Text] [Related]
13. Low Frequency ALK Hotspots Mutations In Neuroblastoma Tumours Detected By Ultra-deep Sequencing: Implications For ALK Inhibitor Treatment.
Javanmardi N; Fransson S; Djos A; Sjöberg RM; Nilsson S; Truvé K; Kogner P; Martinsson T
Sci Rep; 2019 Feb; 9(1):2199. PubMed ID: 30778092
[TBL] [Abstract][Full Text] [Related]
14. Metachronous Medulloblastoma in a Child With Successfully Treated Neuroblastoma: Case Report and Novel Findings of DNA Sequencing.
Eterovic AK; Maher OM; Chandra J; Chen K; Huse J; Zaky W
J Natl Compr Canc Netw; 2018 Jun; 16(6):683-691. PubMed ID: 29891519
[TBL] [Abstract][Full Text] [Related]
15. Clinico-pathological description of three paediatric medulloblastoma cases with MLL2/3 gene mutations.
López GY; Grant GA; Fuchs HE; Leithe LG; Gururangan S; Bigner DD; Yan H; McLendon RE; He Y
Neuropathol Appl Neurobiol; 2014 Feb; 40(2):217-20. PubMed ID: 23659599
[No Abstract] [Full Text] [Related]
16. Deep Sequencing Reveals Occurrence of Subclonal ALK Mutations in Neuroblastoma at Diagnosis.
Bellini A; Bernard V; Leroy Q; Rio Frio T; Pierron G; Combaret V; Lapouble E; Clement N; Rubie H; Thebaud E; Chastagner P; Defachelles AS; Bergeron C; Buchbinder N; Taque S; Auvrignon A; Valteau-Couanet D; Michon J; Janoueix-Lerosey I; Delattre O; Schleiermacher G
Clin Cancer Res; 2015 Nov; 21(21):4913-21. PubMed ID: 26059187
[TBL] [Abstract][Full Text] [Related]
17. Reproducibility of the NanoString 22-gene molecular subgroup assay for improved prognostic prediction of medulloblastoma.
Leal LF; Evangelista AF; de Paula FE; Caravina Almeida G; Carloni AC; Saggioro F; Stavale JN; Malheiros SMF; Mançano B; de Oliveira MA; Luu B; Neder L; Taylor MD; Reis RM
Neuropathology; 2018 Oct; 38(5):475-483. PubMed ID: 30155928
[TBL] [Abstract][Full Text] [Related]
18. [Reliability of molecular tumour markers in children with medulloblastoma--an example from clinical practice].
Pfister S
Z Evid Fortbild Qual Gesundhwes; 2011; 105(7):511-3. PubMed ID: 21958611
[TBL] [Abstract][Full Text] [Related]
19. A CTNNB1-altered medulloblastoma shows the immunophenotypic, DNA methylation and transcriptomic profiles of SHH-activated, and not WNT-activated, medulloblastoma.
Chiang J; Moreira DC; Pytel NJ; Liu YC; Blackburn PR; Shi Z; Cardenas M; Wheeler DA; Furtado LV
Neuropathol Appl Neurobiol; 2022 Aug; 48(5):e12815. PubMed ID: 35320876
[TBL] [Abstract][Full Text] [Related]
20. [Clinicopathological features of lung adenocarcinoma harboring anaplastic lymphoma kinase rearrangements].
Dong Y; Zhou L; Wang J; Cai Y; Mu J; Zhang H
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):436-40. PubMed ID: 26463147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
